A Phase 2 interventional study of MAS825 and Placebo in COVID-19 Pneumonia, Impaired Respiratory Function, sponsored by Novartis Pharmaceuticals. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.
Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 66th largest by enrollment of the 253 interventional ones that give a count, is one of 42 that started in 2020, is one of 28 in phase 2, and was the 233rd registered.
1,369 studies on the registry are indexed under Respiratory Insufficiency; 265 are open to participants now.
Browse Respiratory Insufficiency studies →44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages up to 28 days
University of Rochester · Sites in United States
Ages 18+ · Healthy volunteers
Thomas Jefferson University · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 42 · Phase 3 27 · Phase 4 9
First in 1992; this study’s year is marked. 42 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 42 across the 253 interventional studies, 65 across the 95 observational. Of the 246 that completed or were terminated, 93 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 349 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
24 of the studies in Respiratory Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217197Thomas Jefferson UniversityRespiratory Monitoring System That Detects & Predicts OIRD | 2026-11-30 |
| NCT04664192Baylor Research InstituteBio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research | 2026-12-01 |
| NCT05462600University of California, San DiegoDistribution of Ventilation, Respiratory Drive and Gas Exchange: Measurements and Monitoring | 2026-12-30 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT06938217Institute for Extracorporeal Life SupportSafety and Efficacy of Low-Flow ECMO in a Multi-modal Cohort of Adults in Respiratory Failure | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 349 studies in Respiratory Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.
This was a Phase 2, randomized, placebo -controlled, participant and investigator blinded, multi-center study to assess efficacy and safety of MAS825 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function.
The study consisted of five study periods:
Screening / Baseline / Treatment visit (Day -1 to 1): Lasted up to a maximum of 24 hours and comprised a screening / baseline assessment. This visit was used to confirm that the study inclusion and exclusion criteria were met and served as baseline assessment prior to randomization. Participants were randomized as soon as possible, but within a maximum of 24 hours after screening in a 1:1 ratio receiving a single intravenous infusion of MAS825 or placebo in addition to standard of care (SoC) on Day -1 to 1.
Treatment period (Day 2-15): Study assessments were conducted every 2 days for hospitalized participants. If participants were discharged from the hospital prior to Day 15, assessments on the day of discharge were performed according to the schedule listed under Day 15 and those participants returned to the site for the Day 15 assessment (all other visits between discharge and Day 15 were omitted).
Follow-up (Day 16-29): After completion of the treatment period, participants were observed until Day 29 or discharged from hospital, whichever was sooner. Study assessments were conducted every 2 days for domiciled participants. If participants were discharged from hospital prior to Day 29, a study visit conducted by telephone was performed on Day 29 (all other visits between discharge and Day 29 were omitted).
Safety follow-up visit assessment (Day 45): A follow-up visit for safety was conducted at Day 45 if the participant was hospitalized. If participants were discharged from the hospital prior to Day 45, a study visit was conducted by telephone on Day 45.
End of Study/Safety follow-up visit assessment (Day 127): A follow-up visit for safety was conducted at Day 127 if the participant was hospitalized. If participants were discharged from the hospital prior to Day 127, a study visit was conducted by telephone on Day 127.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous treatment with anti-rejection and immunomodulatory drugs within the past 2 weeks, or within the past 30 days or 5 half-lives (whichever is the longer) for immunomodulatory therapeutic antibodies or prohibited drugs, with the exception of anti-viral therapies or
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of MAS825 10 mg/kg by intravenous infusion in addition to SoC
Drug: MAS825 · Drug: Standard of Care (SoC)
Single dose of matching Placebo by intravenous infusion in addition to SoC
Other: Placebo · Drug: Standard of Care (SoC)
MAS825 liquid solution for intravenous infusion
Placebo liquid solution for intravenous infusion
SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier)
The APACHE II ("Acute Physiology And Chronic Health Evaluation II") is a severity-of-disease classification system. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. In practice, it is rare for any participant to accumulate more than 55 points. APACHE II score was measured on Day 15 or on the day of discharge (whichever was earlier). Participants who died on Day 15 or earlier were assigned the highest observed APACHE II score of any of the participants at any time during the trial (worst case imputation for deaths). Missing data values of the parameters required for the derivation of the APACHE II score were replaced by the last available assessment.
Time frame: up to Day 15
Serum C-reactive Protein (CRP) Levels
C-reactive protein (CRP) is a blood test marker for inflammation in the body. It was analyzed on a log-scale fitting a repeated measures mixed model: treatment, visit, stratification factors, visit \* treatment and visit \* stratification factors as fixed effects and log-transformed baseline score and visit \* log-transformed baseline score as continuous covariate. Values reported were back-transformed to original scale.
Time frame: Baseline, days 2, 4, 6, 8, 10, 12, 14 and 15
Ferritin Levels
Ferritin is a blood test marker for inflammation in the body. For a standard ferritin test, a normal reading is less than 300 micrograms per liter (μg/L). It was analyzed on a log-scale fitting a repeated measures mixed model: treatment, visit, stratification factors, visit \* treatment and visit \* stratification factors as fixed effects and log-transformed baseline score and visit \* log-transformed baseline score as continuous covariate. Values reported were back-transformed to original scale.
Time frame: Baseline, days 2, 4, 6, 8, 10, 12, 14 and 15
Number of Participants Not Requiring Mechanical Ventilation for Survival
Number of participants not requiring mechanical ventilation for survival until Day 15 and Day 29: defined by WHO 9-point ordinal scale score of \< 6 points at all time points assessments. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including Day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.
Time frame: Until Day 15 (Assessments on Days 2, 4, 6, 8, 10, 12, 14 and 15) and until Day 29 (Additional assessments on Days 17, 19, 21, 23, 25, 27 and 29)
Number of Participants With at Least One-point Improvement From Baseline in Clinical Status
Number of participants with at least one-point improvement from baseline in clinical status, which was measured with WHO 9-point ordinal scale. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including Day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.
Time frame: Baseline, Day 15 and Day 29
Clinical Status Over Time
Clinical status was measured with World Health Organization (WHO) 9-point ordinal scale. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 127, the score for death was imputed for all following visits up to and including Day 127. For all the other participants, last observation carried forward was applied up to and including Day 127.
Time frame: Baseline, days 2, 4, 6, 8, 10, 12, 14, 15, 17, 19, 21, 23, 25, 27, 29, 45 and 127
Participants took part in 21 investigative sites in 1 country, United States.
| Milestone | MAS825 + SoC | Placebo + SoC |
|---|---|---|
| Started | 69 | 71 |
| Safety analysis set | 68 | 70 |
| Pharmacokinetics (pk) analysis set | 63 | 0 |
| Completed | 38 | 43 |
| Not completed | 31 | 28 |
| Withdrew: Death | 26 | 23 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Physician decision | 0 | 1 |
The APACHE II ("Acute Physiology And Chronic Health Evaluation II") is a severity-of-disease classification system. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. In practice, it is rare for any participant to accumulate more than 55 points. APACHE II score was measured on Day 15 or on the day of discharge (whichever was earlier). Participants who died on Day 15 or earlier were assigned the highest observed APACHE II score of any of the participants at any time during the trial (worst case imputation for deaths). Missing data values of the parameters required for the derivation of the APACHE II score were replaced by the last available assessment.
| Score on a scale | MAS825 + SoC | Placebo + SoC |
|---|---|---|
| APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier) | 14.5 ± 1.87 | 13.5 ± 1.8 |
C-reactive protein (CRP) is a blood test marker for inflammation in the body. It was analyzed on a log-scale fitting a repeated measures mixed model: treatment, visit, stratification factors, visit \* treatment and visit \* stratification factors as fixed effects and log-transformed baseline score and visit \* log-transformed baseline score as continuous covariate. Values reported were back-transformed to original scale.
| Milligram / Liter | MAS825 + SoC | Placebo + SoC |
|---|---|---|
| Day 2 | 55.50 ± 1.11 | 57.70 ± 1.10 |
| Day 4 | 28.30 ± 1.19 | 37.10 ± 1.19 |
| Day 6 | 19.80 ± 1.24 | 22.30 ± 1.24 |
| Day 8 | 15.00 ± 1.31 | 16.6 ± 1.30 |
| Day 10 | 10.10 ± 1.38 | 19.80 ± 1.35 |
| Day 12 | 11.00 ± 1.42 | 15.80 ± 1.39 |
| Day 14 | 7.30 ± 1.43 | 13.20 ± 1.39 |
| Day 15 | 5.70 ± 1.40 | 11.60 ± 1.36 |
Ferritin is a blood test marker for inflammation in the body. For a standard ferritin test, a normal reading is less than 300 micrograms per liter (μg/L). It was analyzed on a log-scale fitting a repeated measures mixed model: treatment, visit, stratification factors, visit \* treatment and visit \* stratification factors as fixed effects and log-transformed baseline score and visit \* log-transformed baseline score as continuous covariate. Values reported were back-transformed to original scale.
| Microgram / Liter | MAS825 + SoC | Placebo + SoC |
|---|---|---|
| Day 2 | 773.20 ± 1.05 | 800.20 ± 1.05 |
| Day 4 | 692.70 ± 1.05 | 701.40 ± 1.05 |
| Day 6 | 687.50 ± 1.10 | 622.10 ± 1.10 |
| Day 8 | 674.00 ± 1.12 | 667.80 ± 1.11 |
| Day 10 | 670.00 ± 1.16 | 776.00 ± 1.15 |
| Day 12 | 680.00 ± 1.18 | 754.50 ± 1.17 |
| Day 14 | 541.70 ± 1.22 | 595.70 ± 1.22 |
| Day 15 | 502.90 ± 1.21 | 504.20 ± 1.21 |
Number of participants not requiring mechanical ventilation for survival until Day 15 and Day 29: defined by WHO 9-point ordinal scale score of \< 6 points at all time points assessments. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including Day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.
| Participants | MAS825 + SoC | Placebo + SoC |
|---|---|---|
| Until Day 15 | 41 | 47 |
| Until Day 29 | 39 | 45 |
Number of participants with at least one-point improvement from baseline in clinical status, which was measured with WHO 9-point ordinal scale. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including Day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.
| Participants | MAS825 + SoC | Placebo + SoC |
|---|---|---|
| Day 15 | 39 | 39 |
| Day 29 | 43 | 46 |
Clinical status was measured with World Health Organization (WHO) 9-point ordinal scale. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 127, the score for death was imputed for all following visits up to and including Day 127. For all the other participants, last observation carried forward was applied up to and including Day 127.
| Score on a scale | MAS825 + SoC | Placebo + SoC |
|---|---|---|
| Baseline | 4.8 ± 0.38 | 4.7 ± 0.49 |
| Day 2 | 4.8 ± 0.71 | 4.7 ± 0.57 |
| Day 4 | 4.8 ± 0.90 | 4.7 ± 1.13 |
| Day 6 | 4.8 ± 1.27 | 4.7 ± 1.40 |
| Day 8 | 4.9 ± 1.63 | 4.5 ± 1.64 |
| Day 10 | 4.9 ± 1.76 | 4.6 ± 1.80 |
| Day 12 | 5.0 ± 1.97 | 4.7 ± 2.04 |
| Day 14 | 5.0 ± 2.04 | 4.8 ± 2.09 |
| Day 15 | 4.5 ± 2.59 | 4.2 ± 2.58 |
| Day 17 | 4.4 ± 2.64 | 4.2 ± 2.67 |
| Day 19 | 4.4 ± 2.73 | 4.1 ± 2.70 |
| Day 21 | 4.4 ± 2.78 | 4.1 ± 2.71 |
| Day 23 | 4.4 ± 2.78 | 4.1 ± 2.73 |
| Day 25 | 4.4 ± 2.79 | 4.2 ± 2.76 |
| Day 27 | 4.4 ± 2.81 | 4.2 ± 2.76 |
| Day 29 | 4.2 ± 2.99 | 3.8 ± 3.00 |
| Day 45 | 4.0 ± 3.19 | 3.7 ± 3.24 |
| Day 127 | 3.8 ± 3.48 | 3.3 ± 3.41 |
Collected over Adverse events were reported from the date of administration of study treatment to day 127.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MAS825 + SoC | 26/68 (38.2%) | 31/68 (45.6%) | 20/68 (29.4%) |
| Placebo + SoC | 23/70 (32.9%) | 28/70 (40%) | 19/70 (27.1%) |
| Total | 49/138 (35.5%) | 59/138 (42.8%) | 39/138 (28.3%) |
| Event | MAS825 + SoC | Placebo + SoC | Total |
|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 11/68 | 8/70 | 19/138 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 6/68 | 0/70 | 6/138 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 5/68 | 1/70 | 6/138 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/68 | 5/70 | 10/138 |
| COVID-19 pneumoniaInfections and infestations | 2/68 | 4/70 | 6/138 |
| Acute kidney injuryRenal and urinary disorders | 3/68 | 4/70 | 7/138 |
| Septic shockInfections and infestations | 3/68 | 0/70 | 3/138 |
| Cardiac arrestCardiac disorders | 2/68 | 3/70 | 5/138 |
| PancytopeniaBlood and lymphatic system disorders | 2/68 | 0/70 | 2/138 |
| Multiple organ dysfunction syndromeGeneral disorders | 2/68 | 1/70 | 3/138 |
| Event | MAS825 + SoC | Placebo + SoC | Total |
|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 9/68 | 5/70 | 14/138 |
| Pneumonia bacterialInfections and infestations | 6/68 | 2/70 | 8/138 |
| AnxietyPsychiatric disorders | 3/68 | 6/70 | 9/138 |
| HypotensionVascular disorders | 5/68 | 3/70 | 8/138 |
| Urinary tract infectionInfections and infestations | 2/68 | 5/70 | 7/138 |
| Transaminases increasedInvestigations | 0/68 | 5/70 | 5/138 |
| Atrial fibrillationCardiac disorders | 4/68 | 4/70 | 8/138 |
| Age, Continuous(Years) | MAS825 + SoC | Placebo + SoC | Total |
|---|---|---|---|
| Mean | 65.3 ± 12.46 | 63.7 ± 12.91 | 64.5 ± 12.67 |
| Sex: Female, Male(Participants) | MAS825 + SoC | Placebo + SoC | Total |
|---|---|---|---|
| Female | 30 | 23 | 53 |
| Male | 39 | 48 | 87 |
| Race (NIH/OMB)(Participants) | MAS825 + SoC | Placebo + SoC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| Black or African American | 6 | 8 | 14 |
| White | 51 | 52 | 103 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 7 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Jun 2020 to primary completion in Jan 2021, 6 months.
Results were first posted in Apr 2022, 1 year 3 months after primary completion. A results delay was requested in Jul 2021.
Of 30 phase 2 interventional studies under Respiratory Insufficiency, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arumakimig